Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $55.18 USD
Change Today -0.26 / -0.47%
Volume 926.0K
NVO On Other Exchanges
Symbol
Exchange
OTC US
Copenhagen
Mexico
Frankfurt
Frankfurt
As of 8:04 PM 07/2/15 All times are local (Market data is delayed by at least 15 minutes).

novo-nordisk a/s-spons adr (NVO) Snapshot

Open
$54.92
Previous Close
$55.44
Day High
$55.45
Day Low
$54.86
52 Week High
06/11/15 - $58.21
52 Week Low
01/6/15 - $41.72
Market Cap
143.5B
Average Volume 10 Days
1.3M
EPS TTM
--
Shares Outstanding
2.1B
EX-Date
03/19/15
P/E TM
--
Dividend
$0.73
Dividend Yield
1.32%
Current Stock Chart for NOVO-NORDISK A/S-SPONS ADR (NVO)

Related News

No related news articles were found.

novo-nordisk a/s-spons adr (NVO) Details

Novo Nordisk A/S, a healthcare company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Biopharmaceuticals. The Diabetes Care segment covers insulins, GLP-1 analog, obesity, and oral antidiabetic drugs, as well as other protein related products comprising glucagon, protein related delivery systems, and needles. The Biopharmaceuticals segment offers products in the areas of haemophilia care, growth hormone therapy, and hormone replacement therapy. The company markets and distributes its products through its subsidiaries, distributors, and independent agents. Novo Nordisk A/S was founded in 1925 and is headquartered in Bagsvaerd, Denmark.

39,062 Employees
Last Reported Date: 04/30/15
Founded in 1925

novo-nordisk a/s-spons adr (NVO) Top Compensated Officers

Chief Executive Officer and Member of Executi...
Total Annual Compensation: kr15.2M
Chief Financial Officer, Executive Vice Presi...
Total Annual Compensation: kr8.1M
Chief Science Officer, Executive Vice Preside...
Total Annual Compensation: kr8.1M
Chief of Staff, Executive Vice President and ...
Total Annual Compensation: kr5.5M
Executive Vice President of Marketing, Medica...
Total Annual Compensation: kr5.5M
Compensation as of Fiscal Year 2013.

novo-nordisk a/s-spons adr (NVO) Key Developments

Novo Nordisk to Stop Selling Insulin Drug Tresiba in Germany

Novo Nordisk announced that it has decided to stop selling Tresiba, the company's novel long-acting insulin drug, in Germany owing to a disagreement on the medicine's pricing. Novo took the decision after it could not agree on Tresiba's pricing in negotiations with GKV-Spitzenverband, an association of healthcare companies in Germany. At present, nearly 40,000 diabetic patients across Germany use the insulin drug and Novo will not stop the product's supply till the end of September 2015 so as to enable such patients to switch over to another safe insulin alternative. The European Medicines Agency has recognized Tresiba as providing significant benefits, but GKV-Spitzenverband had decided to fix the drug's price at the level of regular human insulin.

Novo Nordisk A/S Announces New Xultophy® (IDegLira) Phase 3b Study on HbA1c Reduction, Body Weight Change and Lower Rate of Hypoglycaemia Versus Insulin Glargine

Novo Nordisk A/S announced new phase 3b findings showed adults with type 2 diabetes treated with Xultophy® (IDegLira), a once-daily, single-injection combination of insulin degludec and liraglutide, demonstrated statistically significant reduction in HbA1c(average blood glucose over the previous three months), change In body weight and a lower rate of hypoglycaemia compared with patients treated with insulin glargine. Findings from the phase 3b DUAL™ V 26-week trial that compared the efficacy and safety of Xultophy® versus insulin glargine, both added on to metformin, in patients with type 2 diabetes uncontrolled on insulin glargine (20-50 units/day), were presented at the 75th Annual Scientific Sessions of the American Diabetes Association (ADA) in Boston, Massachusetts, United States. At 26 weeks, patients randomised to Xultophy® treatment achieved a statistically significant mean reduction in HbA1c of 1.8% from baseline (8.4% to 6.6%) compared with a 1.1% reduction (8.2% to 7.1%) achieved by patients who further increased their dose of insulin glargine (p1]. Also presented during the scientific meeting were additional patient-reported outcomes (PRO) data measured by TRIM-D (Treatment Related Impact Measure-Diabetes) and SF36 v2 (Short-Form 36 Health Survey version 2) from DUAL™ V: Insulin Degludec/Liraglutide (IDegLira) Improves Patient-Reported Impacts in Subjects With Type 2 Diabetes (T2D) Inadequately Controlled on Insulin Glargine (IG) Plus Metformin (Met): DUAL™ V Study (Abstract #2550-PO). Xultophy®: Xultophy® is a once-daily single injection combination of Tresiba® (insulin degludec), a once-daily basal insulin analogue with an ultra-long duration of action and Victoza® (liraglutide), a once-daily human GLP-1 analogue. The maximum dose of Xultophy® is 50 dose steps (equivalent to 50 units of insulin degludec and 1.8 mg of liraglutide). Xultophy® is being investigated in the DUAL™ clinical trial programme which includes two phase 3a and a number of phase 3b trials, encompassing more than 3,500 people with type 2 diabetes. Xultophy® was granted marketing authorisation by the European Commission on 18 September 2014 and approved in Switzerl and on 12 September 2014.

Novo Nordisk Invests USD 225 Million in New Manufacturing Facility in Denmark

Novo Nordisk announced that it is investing DKK1.5 billion (USD 225 million) in a new facility in Kalundborg, Denmark. The facility is intended to produce active ingredients for NovoSeven and future haemophilia treatments. The new 7,500 square meters facility is expected to be fully operational in 2020.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NVO:US $55.18 USD -0.26

NVO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $68.21 USD -0.30
Allergan plc $307.51 USD +0.60
Amgen Inc $153.26 USD -1.73
Biogen Inc $404.28 USD -1.13
Bristol-Myers Squibb Co $67.48 USD -0.19
View Industry Companies
 

Industry Analysis

NVO

Industry Average

Valuation NVO Industry Range
Price/Earnings 33.4x
Price/Sales 10.6x
Price/Book 30.9x
Price/Cash Flow 26.3x
TEV/Sales 8.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NOVO-NORDISK A/S-SPONS ADR, please visit www.novonordisk.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.